Patterns of 21-Gene Assay Testing and Chemotherapy Use in Black and White Breast Cancer Patients

Siegel, 2013, Cancer statistics, 2013, CA Cancer J Clin, 63, 11, 10.3322/caac.21166 Lundh MH, Lampic C, Nordin K, et al. Changes in health-related quality of life by occupational status among women diagnosed with breast cancer-a population-based cohort study. Psychooncology, Published online April 14, 2013; http://dx.doi.org.10.1002/pon.3285. Ganz, 2011, Physical and psychosocial recovery in the year after primary treatment of breast cancer, J Clin Oncol, 29, 1101, 10.1200/JCO.2010.28.8043 Epplein, 2011, Quality of life after breast cancer diagnosis and survival, J Clin Oncol, 29, 406, 10.1200/JCO.2010.30.6951 DeSantis, 2011, Breast cancer incidence rates in U.S. women are no longer declining, Cancer Epidemiol Biomarkers Prev, 20, 733, 10.1158/1055-9965.EPI-11-0061 Harris, 2007, American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer, J Clin Oncol, 25, 5287, 10.1200/JCO.2007.14.2364 Paik, 2004, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, 351, 2817, 10.1056/NEJMoa041588 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. breast cancer. Version 3.2014. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Goldhirsch, 2013, Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013, Ann Oncol, 24, 2206, 10.1093/annonc/mdt303 Albanell, 2012, Prospective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer, Ann Oncol, 23, 625, 10.1093/annonc/mdr278 Asad, 2008, Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?, Am J Surg, 196, 527, 10.1016/j.amjsurg.2008.06.021 Geffen, 2011, The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy, Ann Oncol, 22, 2381, 10.1093/annonc/mdq769 Henry, 2009, The influence of a gene expression profile on breast cancer decisions, J Surg Oncol, 99, 319, 10.1002/jso.21244 Partin, 2011, Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer, Ann Surg Oncol, 18, 3399, 10.1245/s10434-011-1698-z Oratz, 2007, Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer, J Oncol Pract, 3, 182, 10.1200/JOP.0742001 Rayhanabad, 2008, Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm, Am Surg, 74, 887, 10.1177/000313480807401001 Davidson, 2013, A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene recurrence score(R) assay in oestrogen receptor positive node negative breast cancer, Eur J Cancer, 49, 2469, 10.1016/j.ejca.2013.03.009 Jain, 2014, The application of Oncotype DX in early-stage lymph-node-positive disease, Curr Oncol Rep, 16, 360, 10.1007/s11912-013-0360-2 Hassett, 2012, Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer, J Clin Oncol, 30, 2218, 10.1200/JCO.2011.38.5740 Lund, 2012, 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome, Cancer, 118, 788, 10.1002/cncr.26180 Olopade, 2008, Advances in breast cancer: pathways to personalized medicine, Clin Cancer Res, 14, 7988, 10.1158/1078-0432.CCR-08-1211 Wheeler, 2013, Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research, Oncologist, 18, 986, 10.1634/theoncologist.2013-0243 Cunningham, 2010, Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status, Cancer Causes Control, 21, 399, 10.1007/s10552-009-9472-2 Sheppard, 2013, Medical mistrust influences black women's level of engagement in BRCA 1/2 genetic counseling and testing, J Natl Med Assoc, 105, 17, 10.1016/S0027-9684(15)30081-X Lagos, 2008, Social-cognitive aspects of underserved Latinas preparing to undergo genetic cancer risk assessment for hereditary breast and ovarian cancer, Psychooncology, 17, 774, 10.1002/pon.1358 Sheppard, 2011, The role of patient-provider communication for black women making decisions about breast cancer treatment, Psychooncology, 20, 1309, 10.1002/pon.1852 Guth, 2013, Utilization of Oncotype DX in an inner city population: race or place?, Int J Breast Cancer, 2013, 653805, 10.1155/2013/653805 Underhill, 2012, The association of perceived provider-patient communication and relationship quality with colorectal cancer screening, Health Educ Behav, 39, 555, 10.1177/1090198111421800 Mandelblatt, 2010, Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians, J Clin Oncol, 28, 3146, 10.1200/JCO.2009.24.3295 Graves, 2011, Providers' perceptions and practices regarding/BRCA1/2/genetic counseling and testing in African-American women, J Genet Couns, 20, 674, 10.1007/s10897-011-9396-3 Lipkus, 2011, Knowledge about genomic recurrence risk testing among breast cancer survivors, J Cancer Educ, 26, 664, 10.1007/s13187-011-0248-5 Tzeng, 2010, Women's experiences with genomic testing for breast cancer recurrence risk, Cancer, 116, 1992, 10.1002/cncr.24990 Sheppard, 2013, Narrowing racial gaps in breast cancer chemotherapy initiation: the role of the patient-provider relationship, Breast Cancer Res Treat, 139, 207, 10.1007/s10549-013-2520-3 National Comprehensive Cancer Network. The NCCN breast cancer clinical practice guidelines (v. VIII. 2006). http://www.nccn.org. Albain, 2010, Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol, 11, 55, 10.1016/S1470-2045(09)70314-6 Rizzo, 2009, Characteristics and treatment modalities for African-American women diagnosed with stage III breast cancer, Cancer, 115, 3009, 10.1002/cncr.24334 Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8 Bird, 2001, Perceived race-based and socioeconomic status (SES)-based discrimination in interactions with health care providers, Ethn Dis, 11, 554 Makoul, 1995, Health promotion in primary care: physician-patient communication and decision-making about prescription medications, Soc Sci Med, 41, 1241, 10.1016/0277-9536(95)00061-B Thompson, 2005, A pilot, randomized, double-blinded, placebo-controlled trial of individualized homeopathy for symptoms of estrogen withdrawal in breast-cancer survivors, J Altern Complement Med, 11, 13, 10.1089/acm.2005.11.13 Wolf, 2005, Development and validation of the communication and attitudinal self-efficacy scale for cancer (CASE-cancer), Patient Educ Couns, 57, 333, 10.1016/j.pec.2004.09.005 Lukwago, 2001, Development and validation of brief scales to measure collectivism, religiosity, racial pride, and time orientation in urban African-American women, Fam Community Health, 24, 63, 10.1097/00003727-200110000-00008 Chen, 2013, Evaluating use characteristics for the Oncotype DX 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer, J Oncol Pract, 9, 182, 10.1200/JOP.2012.000638 Nguyen, 2014, Impact of Oncotype DX recurrence score in the management of breast cancer cases, Clin Breast Cancer, 14, 182, 10.1016/j.clbc.2013.12.002 DeFrank, 2013, Who gets genomic testing for breast cancer recurrence risk?, Public Health Genomics, 16, 215, 10.1159/000353518 Albain, 2009, Racial disparities in cancer survival among randomized clinical trials patients of the southwest oncology group, J Natl Cancer Inst, 101, 984, 10.1093/jnci/djp175 Siegelmann-Danieli, 2013, The impact of the Oncotype DX recurrence score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi health care services experience with a unified testing policy, Ecancermedicalscience, 7, 380 Richman, 2011, Knowledge of genomic testing among early-stage breast cancer patients, Psychooncology, 20, 28, 10.1002/pon.1699 Ramsey, 2013, Integrating comparative effectiveness design elements and end points into a phase III, randomized clinical trial (SWOG S1007) evaluating Oncotype DX-guided management for women with breast cancer involving lymph nodes, Contemp Clin Trials, 34, 1, 10.1016/j.cct.2012.09.003 Armstrong, 2005, Racial differences in the use of BRCA1/2 testing among women with family history of breast or ovarian cancer, JAMA, 293, 1729, 10.1001/jama.293.14.1729 Susswein, 2008, Increased uptake of BRCA1/2 genetic testing among African-American women with a recent diagnosis of breast cancer, J Clin Oncol, 26, 32, 10.1200/JCO.2007.10.6377 Silva, 2013, Assessing racial/ethnic disparities in chemotherapy treatment among breast cancer patients in context of changing treatment guidelines, Breast Cancer Res Treat, 142, 667, 10.1007/s10549-013-2759-8 Vataire, 2012, Cost-effectiveness of a chemotherapy predictive test, Bull Cancer, 99, 907, 10.1684/bdc.2012.1652